Tower Research Capital (TRC)’s Aquestive Therapeutics AQST Stock Holding History
Bought
Maintained
Sold
Other funds holding AQST
BCM
Tower Research Capital (TRC)'s AQST Position: Q3 2026 in Review
Tower Research Capital (TRC) reduced its Aquestive Therapeutics (AQST) stake by 37% in Q3 2026, selling an estimated $15.1K and leaving 5,774 shares worth $26.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3622.
Tower Research Capital (TRC) first reported a position in AQST in Q4 2018 and has held it in 29 quarters since. The position peaked at $124K in Q1 2024. 188 funds tracked by Wall St. Rank hold AQST as of Q3 2026.
- Tower Research Capital (TRC) held 5,774 shares of Aquestive Therapeutics worth $26.7K as of Q3 2026.
- Tower Research Capital (TRC) sold 3,396 Aquestive Therapeutics shares in Q3 2026, an estimated $15.1K.
- Aquestive Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3622 holding.
- Tower Research Capital (TRC) first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 29 quarters since.
- Tower Research Capital (TRC)'s Aquestive Therapeutics position peaked at $124K in Q1 2024.
- 188 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.